Dividend Stock: MNC pharma major announces one of its highest-ever payouts

GlaxoSmithKline Pharmaceuticals recommended a final dividend of ₹57 per equity share for FY26 on May 13, marking one of the company’s highest shareholder payouts on record, alongside a steady set of fourth-quarter earnings.

The payout is the company’s third-highest dividend to date, after ₹62.5 per share in 2015 and ₹60 per share in 2022.

The MNC drugmaker reported a 5.75% year-on-year rise in net profit to ₹277.9 crore for the quarter ended March 2026, compared with ₹262.8 crore a year earlier.

Revenue increased 2.1% to ₹995.3 crore from ₹974.4 crore in the corresponding quarter last year, while EBITDA rose 5.2% to ₹351 crore from ₹333.5 crore.

Operating margin improved to 35.2% from 34.2% a year ago, supported by better operational efficiencies.

The company’s board recommended a final dividend of ₹57 per equity share of face value ₹10 each for FY26, subject to shareholder approval at the 101st Annual General Meeting scheduled for June 30, 2026.

Also Read: Sharda Cropchem Q4 Results: Agrochemical maker posts 57% profit jump; dividend declared

GSK Pharma has fixed May 29, 2026 as the record date for determining shareholder eligibility for the dividend. If approved at the AGM, the dividend will be paid on or after July 1, 2026, subject to applicable tax deductions.

Following the earnings announcement, shares of GlaxoSmithKline Pharmaceuticals were trading 1.55% lower at ₹2,410.25 on the NSE.

GSK Pharma is the Indian arm of British pharmaceutical major GlaxoSmithKline and operates across prescription medicines and vaccines in India.